December 1, 2025Journal for ImmunoTherapy of CancerOpen Access

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC

View Full Paper

Ask AI

Bookmark

Authors

JMJun MiyakoshiTokyo National Hospital TYTatsuya YoshidaJuntendo University MSMasayuki ShirasawaKitasato University Hospital

Discussion

Member takes

Implication

Observational study shows PD-L1 expression on tumor and immune cells predicts progression-free survival in NSCLC, suggesting role for combination therapy with CTLA-4 blockade.

Key Points

Patients with low PD-L1 tumor scores and high immune cell scores had improved progression-free survival with Nivo+Ipi vs Pembro.
In Nivo+Ipi cohort, high immune cell score (≥1) was linked to median progression-free survival of 7.7 months.
Multiomics analysis indicated tumors with low TPS/high IC scores had the highest tumor mutation burden and regulatory T cell fraction.
Findings suggest potential for CTLA-4 blockade to complement PD-L1 inhibition in selected NSCLC patients.

Cite This Study

Miyakoshi et al. (2025) studied this question.

synapsesocial.com/papers/69402a5e2d562116f29018cf https://doi.org/10.1136/jitc-2025-012880

View Full Paper

Ask AI

Bookmark

Implication

Observational study shows PD-L1 expression on tumor and immune cells predicts progression-free survival in NSCLC, suggesting role for combination therapy with CTLA-4 blockade.

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC

Discussion

Member takes

Implication

Key Points

Cite This Study

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider